Review · Volume 14, Issue 1 · pp. 18–22
The Challenges and Novel Approaches in the Nanoparticle Formulation of DPP Inhibitors
Jaganathan Saravanan1, Sundaramoorthi Revathi1, Paulraj Ponnaiah2, Vitalis Ronald Eden3
- 1Department of Pharmaceutics, School of Pharmacy, Sri Balaji Vidyapeeth (Deemed to be University), Puducherry Campus, Puducherry, Tamil Nadu, India.
- 2Department of Biotechnology, Faculty of Medicine and Bioscience, MAHSA University, Bandar Saujana Putra, Jenjarom, Selangor Darul Ehsan, Malaysia.
- 3Department of Biotechnology, Faculty of Pharmacy, Lincoln University, Petaling Jaya, Sunway City, Malaysia.
Abstract
Drug delivery methods based on nanoparticles have shown great promise in the effective administration of medicinal drugs, such as inhibitors of Dipeptidyl Peptidase (DPP). In the treatment of type 2 diabetes, DPP inhibitors are commonly used, and their formulation as nanoparticles offers numerous advantages, such as enhanced bioavailability, controlled release, and targeted delivery. However, several challenges exist in formulating DPP inhibitors into nanoparticles, including drug stability, particle size control, and sustained release kinetics. This review article aims to discuss the challenges associated with nanoparticle formulation of DPP inhibitors and highlight recent innovative approaches to overcome these limitations.
Keywords: DPP inhibitors; Nanoparticle; Lipid-based
The full text of this article is available as a PDF. Open the PDF.